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Abstract
Background: Colorectal cancer is the third most common cause of cancer death in both males and females in
England. A national bowel cancer screening programme was rolled out in England between 2006 and 2010. In the
post-randomised controlled trials epoch, assessment of the impact of the programme using observational studies is
needed.
This study protocol was set up at the request of the UK Policy Research Unit in Cancer Awareness, Screening and
Early Diagnosis to evaluate the effect of the current bowel cancer screening programme on incidence of advanced
primary colorectal cancer.
Methods/Design: All incident cases of primary colorectal cancer in England will be included. Cases will be
matched to controls with respect to sex, age, area of registration and year of first invitation to screening. Each
evaluation round will cover a 2-year period, starting from January 2012, and ongoing thereafter. In the first instance,
a pilot will be carried out in a single region. Variables related to colorectal tumour pathology will be obtained to
enable selection and matching of cases and controls, and to allow analyses stratification by anatomical subsite
within the bowel. Cases at Duke’s stage B or worse will be considered as "advanced stage". The influence of sex will
also be investigated. The incidence ratio observed in randomised controlled trials between controls (not invited)
and non-attender invitees will be used to correct for self-selection bias overall. Screening participation at other
national screening programmes (cervical, breast) will also be collected to derive a more contemporaneous
adjustment factor for self-selection bias and assess consistency in self-selection correction in female patients.
Full ethical approval was obtained from the Health Research Authority.
Discussion: The case–control design is potentially prone to a number of biases. The size of the planned study, the
design specifications and the development of analytical strategies to cope with bias should enable us to obtain
accurate estimates of reduction in incidence of advanced stage disease. The results of analyses by sex and
anatomical subsite may highlight the potential need for sex-specific recommendations in the programme.
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Background
In England, colorectal cancer (CRC) is the third most
common cancer in men after prostate and lung cancer
and in women, after breast and lung cancer [1].
Meta-analyses of the randomised controlled trials (RCTs)
have demonstrated the efficacy of biennial screening with
guaiac faecal occult blood test (gFOBt) for haemoglobin in
reducing mortality from CRC (rate ratio = 0.88, 95% CI
0.83-0.94, reviewed in [2]), while generally no significant
effect of screening on incidence was found after 14 to
20 years of follow-up. Only one trial, performed in the
USA, demonstrated any significant reduction in CRC inci-
dence, but the validity of this result may be limited due to
the fact that an unusually large proportion of subjects in
the intervention arm underwent colonoscopy [3]. However,
in all the trials, the reduction in mortality was accompanied
by a reduction in advanced stage disease [4-7].
The English Bowel Cancer Screening Programme (NHS
BCSP) began in July 2006 and rolled out incrementally
across the country, achieving national coverage in 2010. It
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initially offered screening to all men and women between
the ages of 60 and 69 years, resident in England and regis-
tered with a general practitioner. In 2010, it was extended
to include everyone up to the age of 74 years inclusive. In-
dividuals aged 75 and over may also self-refer into the
programme [8,9].
A major issue to be addressed by the UK Policy
Research Unit in Cancer Awareness, Screening and Early
Diagnosis (PRU), is the evaluation of the effects of the pol-
icy of CRC screening as delivered by the current national
programme in terms of anticipated benefits. This issue is
particularly relevant as the uptake of population-based
gFOBt screening in the UK is low compared with, for
example, that of mammographic screening [10], and also
varies by age, sex, ethnicity and deprivation status [11-13].
In the post-RCT epoch, assessing the impact of the NHS
BCSP requires the use of observational studies. Recently,
Libby and collaborators [14] reported a significant 10% re-
duction in CRC mortality among invited individuals invited
for screening as part of the UK CRC screening pilot stud-
ies in Scotland (2000–2007, three biennial rounds of
invitation) when compared to a cohort of uninvited
controls matched for age, gender and deprivation, and
followed up to 31 December 2009.
In an ecological study, the same group found trends
towards earlier stage and less advanced disease at diagno-
sis as well as decreasing mortality rates among individuals
invited for screening as part of the pilot compared to gen-
eral population individuals not yet invited for screening
[15]. However, results from trends studies have limited
validity [16].
We chose to address the policy questions using a
retrospective matched case–control design because it is
a powerful tool which has previously been used to great
effect in the assessment of the NHS Cervical Screening
Programme (NHS CSP), informing policy on screening
intervals and age ranges [17], and recently, in the
assessment of the NHS BSP [18].
Because the NHS BCSP is relatively recent (2006
onwards), long-term goals on mortality reduction may
currently be difficult to assess using a retrospective
design; however, this type of design will be helpful in
investigating changes in incidence of advanced stage
CRC, which in turn will indicate the likely future effect
on mortality from the disease.
In the UK, CRC mortality has been declining in the
population since the 1970s: over the last decade death
rates have dropped by around 14%; in contrast, incidence
rates, in particular in men, have been increasing over that
same period [19,20], making the question of the impact of
the NHS BCSP on incidence of advanced stage primary
CRC a very important one.
In addition, the male-to-female ratio for CRC inci-
dence rates varies for different parts of the large bowel
[21]: the majority of rectal cancer cases occur in men
(63%), while colon cancer cases are approximately evenly
divided between men (53%) and women (47%), suggest-
ing the sensitivity of a particular screening strategy may
differ between sexes [2].
To our knowledge, no case–control studies have been
published which looked at the effect of gFOBt on CRC inci-
dence. Two studies have been published which assessed the
impact of immunochemical faecal blood test (FIT) screening
on CRC incidence in Japan, in separate settings [22,23] but
only one of them investigated the effect of FIT on incidence
of advanced stage disease [22]. In this study, cases (N= 349)
diagnosed with advanced stage CRC (T2-T4 in TNM classi-
fication) aged 40 or over were compared to general popula-
tion controls (3 per case) matched for sex, age and area of
residence, with respect to screening history prior to diag-
nosis. The authors found a significant reduction in the
incidence of advanced stage CRC in those who attended
screening within 3 years prior to the date of diagnosis
(OR= 0.54, 95% CI 0.30 – 0.99). No adjustments were made.
In view of the above, there is a need for a large case–
control evaluation of the effect of the NHS BCSP on
incidence of advanced stage CRC with appropriate
methodology for coping with bias, notably self-selection
bias. Meeting the above aims will entail retrieving infor-
mation on tumour pathology variables, and on screening
participation at other national screening programmes.
This will be an ongoing biennial evaluation to ensure that
the programme continues to deliver the anticipated health
benefits, and to potentially improve the programme by
identifying good and bad practices.
The case–control design is potentially prone to a num-
ber of biases, in particular some that could confer a bias
in favour of screening; those will be addressed either at
the design, or at the analysis stage of the study.
Methods/Design
Study design & objectives
The study will be a matched comparison of recently
diagnosed/incident advanced stage primary CRC (colon,
rectosigmoid junction and rectum) cases with general
population controls free of advanced stage disease, with
respect to screening exposure strictly prior to the case's
date of index/first diagnosis (set as pseudo-diagnosis
date in controls). There will be two controls per case.
The primary objective will be to determine whether
the event of having been screened prior to diagnosis is
superior to not having been screened in terms of inci-
dence of advanced stage primary CRC. In addition, we
plan to assess the benefit by time since last negative
screen and number of screens among other measures of
exposure. The secondary objective will be to consider
the effect of screening on overall CRC incidence, regard-
less of stage.
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A methodological objective of this protocol is to apply
a procedure using data from RCTs and from other can-
cer screening programmes, in this case, from the cervical
(NHS CSP) and the breast (NHS BSP) screening pro-
grammes, to adjust the analysis of the case–control stud-
ies for self-selection bias.
Setting & source population
The background, implementation and organisation of
the NHS BCSP are described in detail elsewhere [12].
For this study, all individuals who were invited to par-
ticipate in the NHS BCSP in England (2006 onwards),
and did not express dissent to their records being used
for research, will be targeted.
The evaluation will begin with a pilot phase in one
region in England using cases that were diagnosed with
CRC between the 1st January 2012 and the 31st December
2013. The initial main phase of the study will then be
undertaken, which will cover the whole of England or,
those regions (i.e. previous cancer registries) for which
tumour pathology variables will be available from 1st of
January 2014. In achieving this, we shall put mecha-
nisms in place so that the exercise can be carried out on
a biennial basis.
Participants: selection of cases & controls
Population of incident cases
All individuals who have had primary CRC diagnosed
aged 60–89 within the specified 2-year study period will
be selected. The index diagnosis will be either a first or a
subsequent primary CRC and, therefore, individuals may
have had a previous history of primary CRA or CRC
(Duke A only) prior to the date of their index diagnosis.
Cases may have died from primary CRC (as stated in
part 1 of the death certificate) during the specified
2-year study period, or afterwards. DCO cases will be
excluded. For subsequent phases of this evaluation
(main phase onwards), individuals will not have been
included as cases in previous evaluation periods,
although they may have been included as controls.
Population of case-matched general population controls
For each case, two individuals of the same sex as the
case will be selected from the general population who
were registered in the same National Health Applica-
tions and Infrastructure Services (NHAIS) system as the
case at the case's date of index diagnosis, were alive at
the case’s date of index diagnosis, were born within
1 month either side of the case’s date of birth, and had
had their first invitation to bowel screening in the same
year as the case. If no matched control is found for a
particular case with a date of birth within 1 month
either side of the case's date of birth, the range will be
expanded to 3 months either side (or 6 months either
side if the case’s age at index diagnosis of primary CRC
is over 75). For subsequent phases of this evaluation
(main phase onwards), they will not have been included
as population controls in previous evaluation periods.
Incident advanced stage cases and matched general
population controls will be selected a posteriori by the
PRU according to various designs as described in Table 1.
In the initial stages of the evaluation, incident cases will
be restricted to those individuals with Duke’s stage B or
worse primary CRC at index diagnosis (Designs 1–3).
Data permitting, we will also include individuals diag-
nosed with a Duke's stage A primary CRC during the
study window but who were subsequently found to
develop metastases (i.e. the cancer becomes stage B or
worse) in order to avoid introducing a bias in favour
of screening by excluding them from the population
of cases and underestimating the proportion of Duke
B+ tumours among screen-detected. Indeed, metastases
are more likely to be early and therefore minimal and so
missed in screen-detected compared to symptomatic
cases; as a consequence, a minority of screen-detected
tumours may be classified as having a less advanced
stage leading to the underestimation of screening expos-
ure in cases, and creating a bias in favour of screening.
Matched general population controls will be restricted
to those individuals who have never had stage B or
worse primary CRC, but may have had early stage
primary CRC (Duke’s stage A) or CRA prior to and
including the case's date of index diagnosis. The majority
of controls, will, however, never have had CRC (or CRA).
In later stages of the evaluation, all incident cases will
be considered (Design 4).
All cases and controls will appear on the HSCIC data-
base at Exeter and will have available data on bowel,
cervical (for women aged 60–64) and breast (for women
aged 60–74) screening strictly prior to the date of index/
first diagnosis of the case, depending on the analysis
(that is, they have been invited to screening at least once
prior, see Table 1 for details). Bowel, cervical and breast
screening history as well as primary CRC pathology vari-
ables will be retrieved for all cases and controls. In
addition, history of previous CRA and corresponding
tumour pathology variables will be obtained.
A detailed description of the subject selection criteria
and matching algorithm will be created in collaboration
with our NHS partners.
Data sources & collection
Recently diagnosed cases will be obtained from the
Northern and Yorkshire Cancer Registry and Informa-
tion Service (NYCRIS) which is the lead registry for
colorectal cancer. This cancer registry has linked the
NHS BCSP data to the National Cancer Data Repository
(NCDR) up until 2010 and is planning to update this
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linkage on a regular basis. Matching general population
controls will be retrieved from the Health & Social Care
Information Centre (HSCIC) database at Exeter. Tumour
pathology variables will be obtained from the NCDR,
including Dukes’ stage of disease at diagnosis which is
the only currently nationally available staging variable.
Detailed pathology information is also available via the
NHS BCSP [8]. Bowel cancer, cervical and breast
screening variables will be obtained from the HSCIC.
The data will be checked and cleaned by the PRU
Senior Data Manager, transferred to separate Oracle
tables, and stored on a UNIX server kept in a secure
server room within the Wolfson Institute of Preventive
Medicine. Access to the Oracle database is from PCs on
the Queen Mary University of London secure network
using SQLNET.
All data will be processed in accordance with NHS
Information Governance guidelines (NHS IG Toolkit,
https://www.igt.hscic.gov.uk/).
Variables
A list of all the variables to be retrieved for all subjects,
cases and controls (where applicable) during the ongoing
evaluation study is presented in Table 2. Villousness or
high-grade dysplasia, size (≥10 mm) and number of aden-
omas (≥3) have been found to be the most important pre-
dictors of future CRC [24,25]. Anatomical subsite may also
affect risk as sensitivity of investigation methods may differ
between location (e.g. see [2] for differences with gFOBt).
Power calculation
For the main phase of the study, all cases complying
with the selection criteria in the whole of England cover-
ing the 2-year evaluation period will be collected. We an-
ticipate biennial accrual of thousands of CRC cases (e.g.
33,218 - 18,590 male and 14,628 female cases - in 2010
[19]), for which statistical power will not be an issue and
for which there will be considerable precision.
For the pilot phase of the study, the sample size was
estimated to enable sufficient power to answer the pri-
mary objective with relative confidence.
Nakajima and collaborators [22] found that the odds
ratio of developing advanced stage CRC for those
screened within 2 years before the diagnosis versus
those not screened using a FIT was 0.76 (95% CI 0.45 –
1.28) when both interval and screen-detected cancers
were included in the analysis. We will therefore assume
an odds ratio of 0.8 as FIT has been reported to have a
higher sensitivity compared to gFOBt (reviewed in [2]).
We anticipate 64% agreement of exposure for matched
cases and controls. We further anticipate 55% exposure
for cases, 59% for controls. This would imply that for
39% of case–control pairs, both case and control would
have been exposed to screening, for 25%, neither would
have been exposed, for 16%, the case would have been
exposed and not the control, and for 20% the control
would have been exposed and not the case (illustrated in
Table 3). This would give the expected odds ratio of 0.8.
Table 1 Proposed case–control designs and analyses
Study Criterion Cases Controls
Design 1
Previous
diagnosis
None None
CRA CRA
Duke A CRC Duke A CRC
Index
diagnosis
Duke B+ CRC _
Analysis Exposure to screening prior to first diagnosis of case
Controlling for previous history of CRA & CRC
Adjusting for screen-detection of CRC
Design 2
Previous
diagnosis
None None
CRA CRA
Duke A CRC Duke A CRC
Index
diagnosis
Duke B+ CRC _
Analysis Exposure to screening prior to index diagnosis of case
Controlling for previous history of CRA & CRC
Adjusting for screen-detection of CRC
Design 3
Previous
diagnosis
None None
CRA CRA
Index
diagnosis
Duke B+ CRC _
Analysis Exposure to screening prior to index diagnosis of case
Controlling for previous history of CRA
Design 4
Previous
diagnosis
None None
CRA CRA
Index
diagnosis
Any CRC (Duke A-D) _
Analysis Exposure to screening prior to index diagnosis of case
Controlling for previous history of CRA
Design 5
Previous
diagnosis
None None
CRA CRA
Index
diagnosis
Any CRC (Duke A-D) _
Screen-detected Last screened in same year
as case index screen
Analysis Exposure to screening prior to index diagnosis of case
Controlling for previous history of CRA
CRA: Colorectal Adenoma; CRC: Colorectal Cancer.
Duke A CRC: CRC diagnosed at stage Duke A; Duke B+ CRC: CRC diagnosed at
stage Duke B, C or D.
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To have 90% power to detect this odds ratio as significant
would require 259 discordant pairs and therefore 719 cases
with one control per case [26]. As we propose to have two
controls per case, 719 cases for the pilot study is consider-
ably more than is strictly needed as the number of potential
discordant pairs will be substantially increased.
Missing data for tumour pathology variables can be
close to 30% with more advanced tumours more likely
to have missing pathology data. In a recent retrospective
observational study which used NCDR data, Dukes’
staging was available for 75% of the tumours registered
between July 2006 and December 2008, however this
percentage is likely to increase as time goes on (EJA
Morris, personal communication).
Ninety percent of symptomatic CRC cases have been
shown to be of Duke's stage B or worse [27], but a pro-
portion of 80% at pathological stage B or worse would
be a conservative estimate. Thus, only 56% (0.70 [miss-
ingness] × 0.80 [stage B+]) of the registered CRC cases
will qualify for the study, and we will therefore inflate
the sample size to select N cases so that 0.56*N = 719,
i.e. around 1,300 cases.
As we require information regarding disease stage
and other tumour attributes to select the cases a pos-
teriori, we are planning to collect pilot data from at
least 2,000 cases and twice that number of controls as
a further failsafe measure. In addition to providing
ample power for an odds ratio of 0.8 overall, this will
also (1) provide tighter confidence intervals therefore
impacting on significance, (2) confer the same power
for an odds ratio of 0.7 in a subgroup comprising half
the study population (for example in males, females or
a particular subsite), and (3) allow for the investigation
of the effect of different screening intervals. It is not
clear what we should expect in subgroup analyses, but
the observed results in the pilot will guide us in terms
of the main study.
Bias & effect modification
The case–control design is potentially prone to a number
of biases [28], in particular some that could confer a bias
in favour of screening, and which are addressed either at
the design stage by choosing appropriate selection cri-
teria, or at the analysis stage by using suitable statistical
methods. The selection of participants and choice of ana-
lytic measures of exposure (see Participants: selection of
cases & controls and Statistical Methods sections, respect-
ively) are crucial to ensure accuracy.
Exposure opportunity (frequency) bias
Once diagnosed with cancer, the cases come under clin-
ical management and do not continue with routine
Table 2 Variables of interest for cases and controls
Patient characteristics Primary CRA & CRC pathology variables2 Screening variables3
Patient unique ID Tumour unique ID Screening Health Authority cipher (NHAIS)
NHS number Tumour status Screening office code
Sex Tumour description Screening office reference
Case or control ICD-10 code Year of first invitation to bowel cancer screening
• C18 - Colon
• C19 - Rectosigmoid junction
• C20 - Rectum
Date of birth Dates of diagnoses (all CRAs & CRCs) For bowel/cervical/breast screening
Patient status (Alive or dead at end
of study period)1
Tumour detection mode (all CRAs & CRCs) Episode number
Date of death (where applicable) Anatomical subsite (all CRAs & CRCs) Episode type
Age at death (where applicable) CRC Dukes' stage (& any subsequent restaging) Episode date
Date of index tumour diagnosis CRA villousness Screen date
Age at index tumour diagnosis Tumour size (all CRAs & CRCs) End code
Died of primary CRC (where applicable) Treatment/procedure at diagnosis (all CRAs & CRCs) Flag: NHS or Screening Programme registration
by age 60
Cancer registry Any further treatment/procedure (all CRAs & CRCs)
Geographical area (as available in NCDR) Optional: Dates of treatment (all CRAs & CRCs)
IMD quintile (or postcode)
Ethnicity
1For cases and controls who died after date of index diagnosis of the case.
2Those variables will be retrieved for each neoplasia occurrence.
3All screening history.
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screening as before. The controls, however, will con-
tinue to attend screening. To avoid a potential bias in
favour of screening, controls are given a pseudo-
diagnosis date that is the same as that of their matched
case and screening history is only considered up to that
date [29].
In contrast, the fact of the case having necessarily a
diagnosis of cancer and a control usually not having
such a diagnosis, induces an artificially higher retro-
spective probability of screening exposure in the cases, a
bias against screening (i.e. the screen-detected cases will
always have this screen recorded at diagnosis, whereas the
large majority of controls will not at pseudo-diagnosis
date). Simply excluding the detection screens of the cases
from the histories would bias the results in favour of
screening. A driver of this bias is prevalence screening
and, as the NHS BCSP is a relatively young programme
with at most 3 rounds at the planned start of the pilot
phase (January 2012), this bias may initially be present
although it is likely to decrease for subsequent evaluations.
The extent of screening opportunity bias will be inves-
tigated first, by applying an analytical correction to the
odds ratio using the method developed by Duffy and
collaborators [30], and second, by performing sensitivity
analyses in which the date of pseudo-diagnosis for con-
trols whose matched cases have had a screen-detected
index diagnosis will be extended by up to 3 years, the
estimated average sojourn time for each screen-detected
case, to counteract the artificially higher retrospective
probability of screening exposure in cases [29]. A shorter
sojourn time may however be more appropriate for
screen-detected tumours of stage Duke B or worse [31].
In addition, we will perform a sensitivity analysis using
screen-detected cases only. We will aim to establish
whether such cases were screened less often in the past
than matched controls who were screened at the time of
detection screen of the case [32,33]. In this analysis,
controls that have had a screen in the same year as the
index screen (detection screen) of their matched case will
be included. The index screen will be excluded and the
effect of prior attendance at screening on incidence of
advanced stage primary CRC will be investigated. The im-
pact of being invited to bowel cancer screening prior to
index screen on CRC incidence may also be investigated.
But the major source of bias in case–control studies
where controls are selected from the general population
is potential self-selection bias [34].
Self-selection (volunteer) bias
Individuals who accept the invitation to screening
(attenders) may have an a priori better health status
compared with individuals who do not (non-attenders).
In the case of bowel screening, gFOBt kit return has been
shown to be significantly lower for postcode sectors with
poor health [35]. Therefore attenders at screening may be
less likely to acquire and potentially die from colorectal
cancer. We would anticipate that this will confer a bias
in favour of screening. Although this bias in favour of
screening is unavoidable at the design stage, it can be
approximately corrected for in the statistical analysis.
(1) The regression analyses will be with adjusted for
the Index of Multiple Deprivation (IMD), an area-based
measure of relative deprivation, derived from residents’
postcodes based on census statistics for overcrowded
housing and other factors, and believed to be the main
confounding factor relating to both the exposure (i.e. the
decision to attend screening), and the outcome.
(2) The method developed by Duffy and collaborators
[36] will be used for all patients to correct the estimated
odds ratio using data on participation from the RCTs of
CRC screening, in particular data from the Nottingham
trial (Individual data obtained for the Nottingham trial
from the authors JH Scholefield & SM Moss). In addition,
data from regions with population characteristics (total
population of screening age 60–69, deprivation, ethnicity,
urbanisation status) comparable to areas offered gFOBt
screening may be collected from the early stages of the
NHS BCSP implementation (e.g. 2006–2007) when the
programme had not been fully rolled out [9]. The follow-
ing estimates may then be derived to potentially help
adjust for self-selection bias: (i) CRC incidence among
invited (region 1) screened individuals (i.e. risk among
attenders), (ii) CRC incidence among invited (region 1)
individuals who were not screened (i.e. risk in non-
attenders), and (iii) CRC incidence among individuals
who were not invited (and not screened, region 2).
(3) The method developed by Duffy and collaborators
[36] will also be used for women only to correct the esti-
mated odds ratio using data on participation in the NHS
CSP (cervical) and/or NHS BSP (breast) screening pro-
grammes, rather than data on participation from the
RCTs of mammographic screening. In the absence of
self-selection, the relative risk of primary CRC (death/
incidence) associated with bowel cancer screening for
non-attenders at cervical or breast screening would be
expected to be equal to the relative risk in cervical or
breast screening attenders (after adjusting for bowel cancer
screening). In the Nottingham RCT, the incidence of
Table 3 Power calculation assumptions around exposure
of cases and controls to bowel cancer screening
(percentages)
% Cases
Screened
Cases
Not Screened
Total
Controls - Screened 39 20 59
Controls - Not screened 16 25 41
Total 55 45 100
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primary CRC (all stage) was about 13% higher in non-
attenders to bowel cancer screening compared to at-
tenders (Individual data obtained for the Nottingham
trial from the authors JH Scholefield & SM Moss). The
crucial element in correcting for self-selection bias is the
risk ratio for non-attenders versus attenders to breast/
cervical screening. Thus the correction is estimated only
from data on women as both other screening programmes
apply to women only. This will be calculated for women
who attended bowel screening at least once and for
women who did not attend a single screen, to control for
attendance at bowel cancer screening. A range of denom-
inator values for the risk ratio will be assessed for sensitiv-
ity. One could compare primary CRC rates (i) in women
who have had breast/cervical screening - but not bowel
screening -with women who have had neither breast/cer-
vical nor bowel screening; and (ii) in women who have
had both breast/cervical and bowel screening with women
who have only had bowel screening.
Data for women with age at diagnosis/pseudo-diag-
nosis between 60 and 69 year-old who would have been
invited to both the bowel and breast screening pro-
grammes will be used. Alternatively, data for women
with age at diagnosis/pseudo-diagnosis between 60 and
64 year-old who would have been invited to both the
bowel and cervical screening programmes will be used.
Also, in women under age 60, one could compare pri-
mary CRC rates in women who have, or have not had,
breast/cervical screening, hence by-passing the positive
confounding between uptake of the various screening
programmes.
The national average participation rate at bowel cancer
screening will be obtained for men and women from the
NHS Annual Report on Bowel Cancer Screening [37,12].
For the pilot phase, a single self-selection factor will be
estimated as the data will cover one region only; for the
national phase, regional factors may be estimated to
assess variation in self-selection between regions.
Self-selection will be also addressed at an individual
woman level by adjusting the regression model for par-
ticipation in the other screening programmes, with care-
ful adjustment for the confounding between attendances
in different programmes.
Statistical methods
Case–control study analyses will be conducted using
conditional logistic regression. Matching factors (i.e. age,
area and year of first invitation to bowel cancer screen-
ing) are controlled for in design, and additional analyses
will be stratified by sex and anatomical subsite. All stat-
istical analyses will be performed using the statistical
software STATA version 12 and/or R version 2.13.0.
The primary objective of this case–control will be to
assess the effect of various measures of participation in
bowel cancer screening strictly prior to the case’s date of
index/first diagnosis on incidence from advanced stage
primary CRC (see details in Table 1). The primary meas-
ure of participation to screening will be whether an indi-
vidual ever attended at least one screen episode prior to
diagnosis. Secondary measures will be the total number
of screens, the time since last screen, the time since pen-
ultimate screen, the interval between last screen and
penultimate screen, the maximum interval between 2
screens, the average interval between 2 screens, the total
number of invitations, the patient's age at first screen,
and the patient’s age at last screen.
‘Time since last screen’ will give estimates of the likely
benefit of screening at different intervals. It will include
whether that time span fell within the past two years, as
this corresponds to the NHS BCSP interval and approxi-
mates the estimated preclinical screen-detectable period
(PCDP).
The secondary objective will be to consider the effect
of screening on overall CRC incidence, regardless of
stage. Similar measures of participation will be used.
Self-selection and exposure opportunity biases will be
addressed using the methods described in the Bias &
Effect modification section.
Secondary analyses will consider time since last screen
stratified by age at diagnosis/pseudo-diagnosis, by index/
first tumour detection mode, and by region (Main phase
only). Analysis may be adjusted for stage at diagnosis.
The effect of attending a screen in a particular 5-year
age band (e.g. 60–64), in the pilot phase, or 2-year age
band (e.g. 60–61), in the main phase, on incidence from
advanced stage primary CRC in the subsequent 5-year
age band (i.e. 62–66 or 65–69, respectively) will also be
investigated, as performed for the cervical screening
audit [17]. The results of this analysis should be very
similar to those obtained from the analysis of ‘time since
last screen’ after stratifying the analysis by age at diagno-
sis/pseudo-diagnosis.
In the main phase of the study, the effect of invitation
to bowel screening and attendance at screening prior to
the index screen of the case will also be assessed among
screen-detected cases matched to controls screened
within the same screening interval (Table 1 Design 5).
Discussion
This study protocol addresses the central question of the
effects of the NHS BSCP in terms of the benefits on
incidence of advanced primary colorectal cancer, defined
as pathological Duke’s stage B or worse using a retro-
spective matched case–control study approach.
The attraction of the case–control evaluation strategy
resides in that for a study nested within the cohort of in-
dividuals offered screening, with screening exposure data
prospectively recorded, this design confers a reliability
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and an interpretability comparable with those of a pro-
spective evaluation, while being quick to perform as it
requires no further follow-up. It also directly relates the
clinical endpoint to the screening history at an individual
level, and it requires a relatively small number of cases
and corresponding controls. In addition, the case–con-
trol design allows the assessment of what actually hap-
pened in the population during service screening, taking
into account natural variation. It also has the flexibility
to question aspects of the screening regime, for example
in relation to intervals and target populations, which
were not possible to address using RCT data.
The case–control design is potentially prone to a num-
ber of biases, in particular some that could confer a bias
in favour of screening. However, with careful design and
analysis, one can minimize the risk of biased results.
When the programme is mature, new case–control
studies will be designed to assess the impact of the
programme on mortality from colorectal cancer.
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